106 related articles for article (PubMed ID: 27934878)
1. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.
Möller I; Murali R; Müller H; Wiesner T; Jackett LA; Scholz SL; Cosgarea I; van de Nes JA; Sucker A; Hillen U; Schilling B; Paschen A; Kutzner H; Rütten A; Böckers M; Scolyer RA; Schadendorf D; Griewank KG
Mod Pathol; 2017 Mar; 30(3):350-356. PubMed ID: 27934878
[TBL] [Abstract][Full Text] [Related]
2. Driver mutations in
García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
[TBL] [Abstract][Full Text] [Related]
3. Paired comparisons of mutational profiles before and after brachytherapy in asian uveal melanoma patients.
Lee WS; Lee J; Choi JJ; Kang HG; Lee SC; Kim JH
Sci Rep; 2021 Sep; 11(1):18594. PubMed ID: 34545149
[TBL] [Abstract][Full Text] [Related]
4. GNAQ mutation in a patient with metastatic mucosal melanoma.
Kim CY; Kim DW; Kim K; Curry J; Torres-Cabala C; Patel S
BMC Cancer; 2014 Jul; 14():516. PubMed ID: 25030020
[TBL] [Abstract][Full Text] [Related]
5. GRM1 Gene Fusions as an Alternative Molecular Driver in Blue Nevi and Related Melanomas.
Kervarrec T; Lo Bello G; Pissaloux D; Tirode F; Poulalhon N; Samimi M; Houlier A; de la Fouchardière A
Mod Pathol; 2023 Oct; 36(10):100264. PubMed ID: 37391170
[TBL] [Abstract][Full Text] [Related]
6. INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.
Elbatsh AMO; Amin-Mansour A; Haberkorn A; Textor C; Ebel N; Renard E; Koch LM; Groenveld FC; Piquet M; Naumann U; Ruddy DA; Romanet V; Martínez Gómez JM; Shirley MD; Wipfli P; Schnell C; Wartmann M; Rausch M; Jager MJ; Levesque MP; Maira SM; Manchado E
Nat Cancer; 2024 Mar; 5(3):481-499. PubMed ID: 38233483
[TBL] [Abstract][Full Text] [Related]
7. [Circumscribed choroidal hemangioma and non-pigmented choroidal melanoma: clinical, instrumental and molecular genetic features].
Saakyan SV; Sklyarova NV; Tsygankov AY; Alikhanova VR; Loginov VI; Burdenny AM
Vestn Oftalmol; 2024; 140(2):5-13. PubMed ID: 38742493
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.
Zhou J; Azizan EAB; Cabrera CP; Fernandes-Rosa FL; Boulkroun S; Argentesi G; Cottrell E; Amar L; Wu X; O'Toole S; Goodchild E; Marker A; Senanayake R; Garg S; Åkerström T; Backman S; Jordan S; Polubothu S; Berney DM; Gluck A; Lines KE; Thakker RV; Tuthill A; Joyce C; Kaski JP; Karet Frankl FE; Metherell LA; Teo AED; Gurnell M; Parvanta L; Drake WM; Wozniak E; Klinzing D; Kuan JL; Tiang Z; Gomez Sanchez CE; Hellman P; Foo RSY; Mein CA; Kinsler VA; Björklund P; Storr HL; Zennaro MC; Brown MJ
Nat Genet; 2021 Sep; 53(9):1360-1372. PubMed ID: 34385710
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
Visser M; Papillon JPN; Luzzio M; LaMarche MJ; Fan J; Michael W; Wang D; Zhang A; Straub C; Mathieu S; Kato M; Palermo M; Chen C; Ramsey T; Joud C; Barrett R; Vattay A; Guo R; Bric A; Chung F; Liang G; Romanowski MJ; Lam J; Thohan S; Atassi F; Wylie A; Cooke VG
J Med Chem; 2024 Jan; 67(2):1447-1459. PubMed ID: 38198520
[TBL] [Abstract][Full Text] [Related]
10. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
[TBL] [Abstract][Full Text] [Related]
11. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.
Posch C; Latorre A; Crosby MB; Celli A; Latorre A; Vujic I; Sanlorenzo M; Green GA; Weier J; Zekhtser M; Ma J; Monico G; Char DH; Jusufbegovic D; Rappersberger K; Somoza Á; Ortiz-Urda S
Biomed Microdevices; 2015 Feb; 17(1):15. PubMed ID: 25653058
[TBL] [Abstract][Full Text] [Related]
12. Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations.
Gestrich CK; Vivero MP; Konczyk DJ; Goss JA; Labow BI; Pearson GD; Cottrell CE; Mathew MT; Prasad V; Kozakewich HP; Fletcher CDM; Greene AK; Al-Ibraheemi A
Am J Surg Pathol; 2024 Jan; 48(1):106-111. PubMed ID: 37750536
[TBL] [Abstract][Full Text] [Related]
13. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
14. GNAQ-mutated primary subcutaneous blue melanoma arising in naevus of Ota presenting as a skin-coloured forehead mass.
Santiago S; Roy SF; Tran TT; Bosenberg M; Weston GK
Pathology; 2024 Apr; 56(3):426-428. PubMed ID: 37872018
[No Abstract] [Full Text] [Related]
15. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract][Full Text] [Related]
16. GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics.
Zecchin D; Knöpfel N; Gluck AK; Stevenson M; Sauvadet A; Polubothu S; Barberan-Martin S; Michailidis F; Bryant D; Inoue A; Lines KE; Hannan FM; Semple RK; Thakker RV; Kinsler VA
J Invest Dermatol; 2024 Apr; 144(4):811-819.e4. PubMed ID: 37802293
[TBL] [Abstract][Full Text] [Related]
17. Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy.
Kim V; Guberina M; Bechrakis NE; Lohmann DR; Zeschnigk M; Le Guin CHD
Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):35. PubMed ID: 37862025
[TBL] [Abstract][Full Text] [Related]
18. Targeting Oncogenic Gα
Lapadula D; Benovic JL
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944815
[TBL] [Abstract][Full Text] [Related]
19. Pathological and Molecular Diagnosis of Uveal Melanoma.
Păsărică MA; Curcă PF; Dragosloveanu CDM; Grigorescu AC; Nisipașu CI
Diagnostics (Basel); 2024 May; 14(9):. PubMed ID: 38732371
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives.
Croce M; Ferrini S; Pfeffer U; Gangemi R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31216772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
